BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
25.4 EUR
+1.05 (+4.31%)
We assign a fundamental rating of 4 out of 10 to BLC. BLC was compared to 29 industry peers in the Health Care Providers & Services industry. BLC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BLC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year BLC was profitable.
BLC had a positive operating cash flow in the past year.
Of the past 5 years BLC 4 years were profitable.
In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of 0.08%, BLC is not doing good in the industry: 68.97% of the companies in the same industry are doing better.
The Return On Equity of BLC (0.74%) is worse than 65.52% of its industry peers.
BLC's Return On Invested Capital of 6.37% is fine compared to the rest of the industry. BLC outperforms 62.07% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 6.33%.
The 3 year average ROIC (6.13%) for BLC is below the current ROIC(6.37%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROIC | 6.37% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.22%
ROIC(3y)6.13%
ROIC(5y)5.72%
1.3 Margins
With a Profit Margin value of 0.11%, BLC is not doing good in the industry: 68.97% of the companies in the same industry are doing better.
BLC's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 8.14%, BLC is doing good in the industry, outperforming 62.07% of the companies in the same industry.
In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
BLC has a better Gross Margin (67.80%) than 75.86% of its industry peers.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.14% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.34%
OM growth 5Y0.66%
PM growth 3Y-66.7%
PM growth 5Y-48.68%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BLC is still creating some value.
Compared to 1 year ago, BLC has about the same amount of shares outstanding.
Compared to 5 years ago, BLC has about the same amount of shares outstanding.
The debt/assets ratio for BLC has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.39, we must say that BLC is in the distress zone and has some risk of bankruptcy.
BLC has a Altman-Z score of 1.39. This is in the lower half of the industry: BLC underperforms 65.52% of its industry peers.
BLC has a debt to FCF ratio of 12.84. This is a negative value and a sign of low solvency as BLC would need 12.84 years to pay back of all of its debts.
BLC has a Debt to FCF ratio (12.84) which is in line with its industry peers.
BLC has a Debt/Equity ratio of 5.31. This is a high value indicating a heavy dependency on external financing.
BLC's Debt to Equity ratio of 5.31 is on the low side compared to the rest of the industry. BLC is outperformed by 86.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.31 | ||
| Debt/FCF | 12.84 | ||
| Altman-Z | 1.39 |
ROIC/WACC1.27
WACC5.02%
2.3 Liquidity
BLC has a Current Ratio of 1.39. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
BLC has a better Current ratio (1.39) than 75.86% of its industry peers.
A Quick Ratio of 1.19 indicates that BLC should not have too much problems paying its short term obligations.
BLC's Quick ratio of 1.19 is fine compared to the rest of the industry. BLC outperforms 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
BLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.33%, which is quite impressive.
BLC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -46.37% yearly.
BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.35%.
Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
BLC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.18% yearly.
The Revenue is expected to grow by 7.69% on average over the next years.
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 362.86, which means the current valuation is very expensive for BLC.
72.41% of the companies in the same industry are cheaper than BLC, based on the Price/Earnings ratio.
BLC is valuated expensively when we compare the Price/Earnings ratio to 27.00, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 10.16 indicates a reasonable valuation of BLC.
89.66% of the companies in the same industry are more expensive than BLC, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.70. BLC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 362.86 | ||
| Fwd PE | 10.16 |
4.2 Price Multiples
89.66% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BLC is valued a bit cheaper than 79.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.85 | ||
| EV/EBITDA | 5.61 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BLC does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)19.11
PEG (5Y)N/A
EPS Next 2Y0.72%
EPS Next 3Y6.18%
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:BLC (1/9/2026, 5:16:26 PM)
25.4
+1.05 (+4.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.61%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap187.20M
Revenue(TTM)491.18M
Net Income(TTM)530.00K
Analysts83.33
Price Target36.72 (44.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.55%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 362.86 | ||
| Fwd PE | 10.16 | ||
| P/S | 0.38 | ||
| P/FCF | 5.85 | ||
| P/OCF | 2.03 | ||
| P/B | 2.6 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.61 |
EPS(TTM)0.07
EY0.28%
EPS(NY)2.5
Fwd EY9.84%
FCF(TTM)4.34
FCFY17.09%
OCF(TTM)12.48
OCFY49.15%
SpS66.65
BVpS9.77
TBVpS-16.27
PEG (NY)19.11
PEG (5Y)N/A
Graham Number3.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROCE | 8.67% | ||
| ROIC | 6.37% | ||
| ROICexc | 6.75% | ||
| ROICexgc | 12.06% | ||
| OM | 8.14% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.51% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.22%
ROIC(3y)6.13%
ROIC(5y)5.72%
ROICexc(3y)6.56%
ROICexc(5y)6.11%
ROICexgc(3y)13.97%
ROICexgc(5y)12.75%
ROCE(3y)8.35%
ROCE(5y)7.8%
ROICexgc growth 3Y2.87%
ROICexgc growth 5Y-0.99%
ROICexc growth 3Y7.59%
ROICexc growth 5Y0.26%
OM growth 3Y5.34%
OM growth 5Y0.66%
PM growth 3Y-66.7%
PM growth 5Y-48.68%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score7
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.31 | ||
| Debt/FCF | 12.84 | ||
| Debt/EBITDA | 3.78 | ||
| Cap/Depr | 98.36% | ||
| Cap/Sales | 12.22% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.12% | ||
| Profit Quality | 6037.74% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 1.39 |
F-Score7
WACC5.02%
ROIC/WACC1.27
Cap/Depr(3y)93.08%
Cap/Depr(5y)92.09%
Cap/Sales(3y)11.16%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y18.99%
EPS Next 2Y0.72%
EPS Next 3Y6.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
EBIT growth 1Y17.78%
EBIT growth 3Y7.03%
EBIT growth 5Y5.81%
EBIT Next Year137.78%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y1.88%
FCF growth 3Y107.42%
FCF growth 5Y33.53%
OCF growth 1Y13.78%
OCF growth 3Y17.4%
OCF growth 5Y14.22%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a valuation rating of 4 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the expected EPS growth for BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The Earnings per Share (EPS) of BASTIDE LE CONFORT MEDICAL (BLC.PA) is expected to grow by 18.99% in the next year.
Can you provide the dividend sustainability for BLC stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.55%.